Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. November 2025 08:30 ET | Quelle: Chiesi Group

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to...
12. November 2025 08:30 ET | Quelle: Chiesi Group

Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to...
06. Oktober 2025 07:00 ET | Quelle: Chiesi Group

Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programmes

Exclusive collaboration and license agreement for the development and global commercialisation of Arbor’s clinical-stage gene editing programme, ABO-101 for primary hyperoxaluria type 1...
06. Oktober 2025 07:00 ET | Quelle: Chiesi Group

Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programs

Exclusive collaboration and license agreement for the development and global commercialization of Arbor’s clinical-stage gene editing program, ABO-101 for primary hyperoxaluria type 1 (PH1)Multitarget...
11. Juni 2025 08:00 ET | Quelle: Chiesi Group

Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders

Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership initiated...
11. Juni 2025 08:00 ET | Quelle: Chiesi Group

Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders

Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership...